-  The investment promotes the creation of additional high-skilled jobs

-  As part of WuXi Biologics' global manufacturing network, a new drug product fill line is being installed at its Leverkusen site and the total biomanufacturing capacity is expected to double at its Wuppertal site

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it will increase manufacturing capacity in Germany.

Since 2020, WuXi Bio has significantly invested in the purchase, construction and adaptations of two state-of-the-art manufacturing facilities in Germany, enabling the company to offer end-to-end services spanning the entire biologics manufacturing process. The sterile filling and freeze-drying plant at Chempark Leverkusen, with an annual capacity of approximately ten million doses, is being expanded to include a second variable filling line. The state-of-the-art drug substance facility in Wuppertal is expected to double its total capacity from 12,000L to 24,000L on 30,000 square metres.

Together with the drug product facility in Leverkusen, the expanded drug substance facility in Wuppertal will further enhance WuXi Bio's clinical and commercial manufacturing capacities in Europe. This expansion will strengthen WuXi Bio's global dual-sourcing network strategy, which ensures that materials can be sourced and products manufactured at multiple sites within the company's network.

WuXi Biologics Germany GmbH currently employs a growing team of more than 360 highly skilled people at both sites in Leverkusen and Wuppertal.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "The investment in our facilities in Germany will add new capacity and enhance our existing manufacturing services, which will strengthen our team's ability to deliver timely support to our global clients to advance their biologics towards commercialization. As a trusted partner to global healthcare companies and a strong contributor to the local community, we look forward to providing more efficient and cost-effective processes and enabling our clients to bring new biologics to life for patients."

Dr. Benjamin Minow, Managing Director of WuXi Biologics Germany GmbH, added, "WuXi Biologics' increased capacity in Germany is intended to meet the growing needs of our global customers, especially those in Europe, thereby aligning us with the company's global strategy to work in close proximity to our clients. Germany is a leading biotech and pharma hub. The expansion of the two facilities is a clear commitment to Germany and Europe as high-tech locations and WuXi Biologics' long-term growth strategy."